Is Halozyme the Perfect Stock?

Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you could possibly want?

One thing's for sure: You'll never discover truly great investments unless you actively look for them. Let's discuss the ideal qualities of a perfect stock, then decide if Halozyme (Nasdaq: HALO  ) fits the bill.

The quest for perfection
Stocks that look great based on one factor may prove horrible elsewhere, making due diligence a crucial part of your investing research. The best stocks excel in many different areas, including these important factors:

  • Growth. Expanding businesses show healthy revenue growth. While past growth is no guarantee that revenue will keep rising, it's certainly a better sign than a stagnant top line.
  • Margins. Higher sales mean nothing if a company can't produce profits from them. Strong margins ensure that company can turn revenue into profit.
  • Balance sheet. At debt-laden companies, banks and bondholders compete with shareholders for management's attention. Companies with strong balance sheets don't have to worry about the distraction of debt.
  • Money-making opportunities. Return on equity helps measure how well a company is finding opportunities to turn its resources into profitable business endeavors.
  • Valuation. You can't afford to pay too much for even the best companies. By using normalized figures, you can see how a stock's simple earnings multiple fits into a longer-term context.
  • Dividends. For tangible proof of profits, a check to shareholders every three months can't be beat. Companies with solid dividends and strong commitments to increasing payouts treat shareholders well.

With those factors in mind, let's take a closer look at Halozyme.


What We Want to See


Pass or Fail?

Growth 5-Year Annual Revenue Growth > 15% 124.6% Pass
  1-Year Revenue Growth > 12% 311.7% Pass
Margins Gross Margin > 35% 99.5% Pass
  Net Margin > 15% (35.2%) Fail
Balance Sheet Debt to Equity < 50% 0% Pass
  Current Ratio > 1.3 3.70 Pass
Opportunities Return on Equity > 15% (126.5%) Fail
Valuation Normalized P/E < 20 NM NM
Dividends Current Yield > 2% 0% Fail
  5-Year Dividend Growth > 10% 0% Fail
  Total Score   5 out of 9

Source: S&P Capital IQ. NM = not meaningful due to negative earnings. Total score = number of passes.

With five points, Halozyme seems closer to perfection than it actually is. The stock has been a highflier lately, raising concerns that the company is getting ahead of itself.

Halozyme is a biopharmaceutical company that has a promising pipeline. Last summer, the company got the attention of investors when it announced huge revenue growth resulting from ViroPharma (Nasdaq: VPHM  ) and Baxter International (NYSE: BAX  ) having licensed its enzyme technology. Then, later last year, Halozyme's breast cancer drug Herceptin reported favorable phase 3 trial results, helping to push the stock further into the limelight. Furthermore, the company has the support of insiders, with some big purchases last summer having resulted in big profits.

Yet just earlier this week, Halozyme's stock plunged after a Jefferies analyst downgraded the stock. Yet for the most part, the analyst's primary argument was that the shares were overpriced, suggesting that the current price already reflects any reasonable good news that's likely to come in the near future. Moreover, Halozyme did a secondary offering to raise about $83 million in capital at a price just below where the stock now trades after the decline. Peers Dendreon (Nasdaq: DNDN  ) and Vertex Pharmaceuticals (Nasdaq: VRTX  ) both issued similarly dilutive secondary offerings in their day, using big price spikes to cash in while the time was right, and those offerings often killed momentum in the stock, at least in the short run.

For Halozyme to keep improving, it needs to get past licensing revenue to create a blockbuster drug of its own. If Herceptin proves to be that drug, then Halozyme could move toward perfection in a hurry.

Keep searching
No stock is a sure thing, but some stocks are a lot closer to perfect than others. By looking for the perfect stock, you'll go a long way toward improving your investing prowess and learning how to separate out the best investments from the rest.

Halozyme may not be the perfect stock, but we've got some ideas you may like better. Let me invite you to learn about three smart long-term stock plays in the Fool's latest special report. It's yours for the taking and is absolutely free, but don't miss out -- click here and read it today.

Click here to add Halozyme to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Fool contributor Dan Caplinger doesn't own shares of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Vertex Pharmaceuticals. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1859469, ~/Articles/ArticleHandler.aspx, 5/24/2016 8:30:46 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Caplinger

Dan Caplinger has been a contract writer for the Motley Fool since 2006. As the Fool's Director of Investment Planning, Dan oversees much of the personal-finance and investment-planning content published daily on With a background as an estate-planning attorney and independent financial consultant, Dan's articles are based on more than 20 years of experience from all angles of the financial world.

Today's Market

updated 11 hours ago Sponsored by:
DOW 17,492.93 -8.01 -0.05%
S&P 500 2,048.04 -4.28 -0.21%
NASD 4,765.78 -3.78 -0.08%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/23/2016 4:00 PM
HALO $9.32 Up +0.17 +1.86%
Halozyme Therapeut… CAPS Rating: ****
BAX $42.70 Down -0.22 -0.51%
Baxter Internation… CAPS Rating: ****
DNDNQ $0.03 Down +0.00 +0.00%
Dendreon Corp CAPS Rating: *
VPHM $0.00 Down +0.00 +0.00%
ViroPharma, Inc. CAPS Rating: ***
VRTX $84.42 Down -0.28 -0.33%
Vertex Pharmaceuti… CAPS Rating: ***